BPC-157 Dosage Calculator
Work out your BPC-157 reconstitution concentration, draw volume, and syringe units from your vial size, diluent, and target amount — cross-checked against the published animal-study and Phase II human-trial dosing literature.
Common research vials come in 2 mg, 5 mg, and 10 mg strengths.
2 mL is the most common reconstitution volume for a 5 mg vial; some protocols use 1–3 mL.
Most commonly reported amounts in the literature fall between 250–500 mcg. This field does not recommend a dose — enter your own predetermined figure.
Draw to
—
units on your syringe
How BPC-157 reconstitution math works
BPC-157 ships as a freeze-dried (lyophilized) powder that has to be dissolved in liquid before it can be measured into a syringe. Once bacteriostatic or sterile water is added, the peptide disperses evenly through that liquid, so the strength of the resulting solution depends on exactly two numbers: how many micrograms are in the vial, and how much liquid you added. This bpc 157 dosage calculator runs that same underlying formula used across the site’s Peptide Calculator hub, applied here specifically to BPC-157’s typical vial sizes.
volume to draw (mL) = target amount (mcg) ÷ concentration (mcg/mL)
syringe units = volume to draw (mL) × syringe scale (100 for U-100, 40 for U-40)
Worked example
A 5 mg (5,000 mcg) vial mixed with 2 mL of bacteriostatic water gives a concentration of 2,500 mcg/mL. To reach a 500 mcg amount, you’d draw 0.2 mL — which reads as 20 units on a U-100 insulin syringe. That single vial holds roughly 10 doses of that size before it’s empty.
BPC-157’s legal status in 2026
BPC-157 has never received FDA approval as a drug, and it has no monograph in the United States Pharmacopeia. Its compounding status, however, has shifted meaningfully in 2026, and most existing guides on the internet are already out of date. Here’s the sequence of events as they’ve actually unfolded.
2023
The FDA placed BPC-157 in Category 2 of its 503A bulk drug substances list, a classification reserved for substances the agency considers to carry significant safety risk. This blocked state-licensed compounding pharmacies from legally preparing BPC-157 capsules, injectables, or topicals for patients.
April 2026
The FDA removed BPC-157 from Category 2, along with TB-500 and several other widely discussed peptides, after their Category 2 nominations were withdrawn. This lifted the explicit compounding prohibition.
July 23–24, 2026
The FDA’s Pharmacy Compounding Advisory Committee is scheduled to formally review BPC-157 (free base and acetate forms) for potential addition to the 503A Bulks List, which would establish it as a permitted compounding substance rather than an unresolved one.
Current status
BPC-157 sits in a regulatory gray zone: it’s no longer explicitly barred from compounding, but it also hasn’t been added to the permitted Category 1 list, doesn’t have FDA drug approval, and doesn’t have a USP/NF monograph. Whether an individual pharmacy will compound it is a matter of that pharmacy’s own compliance judgment, not a settled legal green light.
This status can change again after the July 2026 committee review, so treat any claim about BPC-157’s legality as time-stamped, and verify current status directly with the FDA’s 503A Bulks List page before relying on it.
BPC-157 dosing ranges reported in the research literature
There is no FDA-approved dose for BPC-157 and no published human dose-finding trial for injectable use. The figures below are what’s actually reported in the animal-study literature and the one significant human trial, summarized for reference — not a personalized recommendation. This calculator does not compute a suggested dose from your body weight; it only converts an amount you already have in mind into a draw volume.
| Source / context | Reported amount | Route | Notes |
|---|---|---|---|
| Standard animal-study dose | 10 mcg/kg body weight | Intraperitoneal or oral (rats) | The dose used across most of the Zagreb group’s published tendon, gut, and muscle-healing studies |
| Allometric human extrapolation | ≈200–800 mcg/day | N/A — scaled estimate | Derived mathematically from the 10 mcg/kg animal dose; not itself a studied human amount |
| Most commonly reported amount | 250–500 mcg/day | Subcutaneous, split into 1–2 injections | The range most frequently cited across research-community protocols and practitioner guides |
| Phase II human trial (PL 14736) | Not disclosed in mcg for injectable use | Rectal enema, oral | Ulcerative colitis trial; the only controlled human data published on this compound |
The wide spread between the lowest and highest figures in animal models is itself notable: BPC-157 has shown effects across a dose range spanning several orders of magnitude in rodent studies, which is unusual pharmacology and part of why no single “correct” human dose has been established. Because this compound has no verified human dosing standard, decisions about amount, frequency, and duration belong with a licensed healthcare provider, not with an online calculator.
Mechanism, briefly
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid fragment derived from a protective protein naturally present in human gastric juice, which is part of why it’s stable in the stomach where most peptides break down. It doesn’t work like a hormone with a single receptor; published reviews from the University of Zagreb group that has produced most of the primary research describe a pleiotropic mechanism touching angiogenesis (new blood vessel formation via VEGF and the NO-system), modulation of growth-factor receptor pathways in damaged tissue, and effects on the FAK-paxillin signaling pathway involved in cell migration. In practical terms, animal studies report accelerated healing across tendon, ligament, muscle, nerve, and gut tissue, largely attributed to this angiogenic and cytoprotective activity rather than a single targeted action.
Reported plasma half-life is short — roughly 30–60 minutes — which is consistent with once- or twice-daily subcutaneous dosing conventions in the research community, on the reasoning that healing-cascade activity outlasts the compound’s measurable presence in circulation.
Oral vs. injectable BPC-157
BPC-157 is one of the few research peptides with meaningful stability in gastric acid, since it originates from a gastric-juice-derived protein in the first place. That gives it a genuine oral route, unlike most peptides that require injection to survive digestion intact. Practically, research discussions tend to separate the two routes by target: oral or capsule forms are more often discussed for gut-related applications, since the compound contacts the gastrointestinal lining directly, while subcutaneous injection is more often discussed for musculoskeletal applications — tendon, ligament, and joint tissue — where systemic circulation carries the peptide to the injury site. This calculator handles the injectable reconstitution math; oral capsule dosing follows the manufacturer’s stated mcg-per-capsule label rather than a reconstitution formula.
Storage and stability after reconstitution
Unreconstituted (lyophilized) BPC-157 powder is generally reported stable at room temperature for up to about 3 months, and considerably longer — commonly cited around 2 years — when kept refrigerated and protected from light. Once reconstituted with bacteriostatic or sterile water, the solution should be refrigerated and is generally treated as good for roughly 1–2 weeks, since peptide stability in solution gradually declines with time and with repeated temperature swings. Avoid shaking the vial vigorously during mixing — gently swirl instead, as agitation can denature the peptide.
Cycle length conventions reported in practice
Published research protocols and practitioner guides commonly describe BPC-157 use in defined cycles rather than indefinite daily use. A 4–6 week cycle is the most frequently cited window for a single course, with some chronic-condition protocols extending to 8–12 weeks. A break of 2–4 weeks between cycles is commonly reported as well. As with dosing amounts, there’s no clinical trial establishing an optimal cycle length in humans — these figures reflect reported practice, not an evidence-based standard, and cycle planning is a decision to make with a healthcare provider familiar with your specific situation.
Frequently asked questions
The most commonly reported amount across research-community protocols is 250–500 mcg per day, often split into two injections. This figure comes from allometric scaling of animal-study data, not a validated human clinical trial, since no such trial for injectable BPC-157 has been published.
Divide your target amount in mcg by your solution’s concentration in mcg/mL. Concentration itself equals the total peptide in the vial (mcg) divided by the diluent volume you added (mL). The calculator above performs both steps and also converts the result to syringe units.
It’s not FDA-approved as a drug, but it was removed from the FDA’s Category 2 restricted-compounding list in April 2026. A Pharmacy Compounding Advisory Committee review scheduled for July 23–24, 2026 will help determine whether it moves to the permitted 503A Bulks List. Its status can change; check the FDA’s own 503A Bulks List page for the current picture.
It depends entirely on your reconstitution concentration. For example, a 5 mg vial mixed with 2 mL of water yields 2,500 mcg/mL, so 250 mcg would draw to 0.1 mL, or 10 units on a U-100 insulin syringe. Enter your own vial and water numbers above for an exact figure.
Both are studied for tissue-repair applications but are structurally distinct peptides with different reported mechanisms — BPC-157 is a gastric-juice-derived pentadecapeptide associated with angiogenesis and gut protection, while TB-500 is a synthetic fragment of thymosin beta-4 associated with actin regulation and cell migration. They’re dosed separately and are sometimes used together in what’s informally called a stacked protocol, but the reconstitution math for each is calculated independently.
No — the syringe type only changes how the same liquid volume is displayed. A U-100 and U-40 insulin syringe both hold 1 mL in the barrel; they simply print a different unit scale next to the plunger for that same 1 mL.
No. It performs the arithmetic of concentration and draw volume based on numbers you enter yourself. It doesn’t evaluate, suggest, or validate whether any particular amount, product, or schedule is appropriate for you.
Related peptide calculators
References
- Staresinic M, Sebecic B, Patrlj L, et al. “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.” Journal of Orthopaedic Research, 2003;21(6):976–983. View study
- Sikiric P, Seiwerth S, Skrtic A, et al. “Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.” Pharmaceuticals, 2025;18(6):928. Read on PMC
- Seiwerth S, Milavic M, Vukojevic J, et al. “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.” Frontiers in Pharmacology, 2021. Read on Frontiers
- Ruenzi M, Stolte M, Veljaca M, et al. “A multicenter, randomized, double blind, placebo controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis.” Gastroenterology, 2005;128:A584.
- U.S. Food & Drug Administration — 503A Bulks List, Category 2 substances
- U.S. Food & Drug Administration — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting notice